{
    "organizations": [],
    "uuid": "7c97ba2b5abe0f85474c13b7db7764c60256e331",
    "author": "",
    "url": "https://www.reuters.com/article/brief-janssen-announces-darzalex-us-fda/brief-janssen-announces-darzalex-u-s-fda-approval-for-patients-with-multiple-myeloma-idUSASC0A0B2",
    "ord_in_thread": 0,
    "title": "BRIEF-Janssen Announces Darzalex U.S. FDA Approval For Patients With Multiple Myeloma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 7 (Reuters) -\n* JANSSEN ANNOUNCES DARZALEXÂ® (DARATUMUMAB) U.S. FDA APPROVAL FOR NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE\n* JANSSEN PHARMA - FDA APPROVAL OF DARZALEX IN COMBINATION WITH BORTEZOMIB, MELPHALAN AND PREDNISONE MARKS ITS FIFTH INDICATION IN MULTIPLE MYELOMA Source text for Eikon:\nOur ",
    "published": "2018-05-08T05:46:00.000+03:00",
    "crawled": "2018-05-08T06:00:25.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "janssen",
        "announces",
        "daratumumab",
        "fda",
        "approval",
        "newly",
        "diagnosed",
        "patient",
        "multiple",
        "myeloma",
        "transplant",
        "ineligible",
        "janssen",
        "pharma",
        "fda",
        "approval",
        "darzalex",
        "combination",
        "bortezomib",
        "melphalan",
        "prednisone",
        "mark",
        "fifth",
        "indication",
        "multiple",
        "myeloma",
        "source",
        "text",
        "eikon"
    ]
}